Annual report pursuant to Section 13 and 15(d)


Cover - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2022
Feb. 17, 2023
Jun. 30, 2022
Document Information Line Items      
Entity Registrant Name DERMATA THERAPEUTICS, INC.    
Entity Central Index Key 0001853816    
Document Type 10-K/A    
Amendment Flag true    
Entity Voluntary Filers No    
Current Fiscal Year End Date --12-31    
Entity Well Known Seasoned Issuer No    
Entity Small Business true    
Entity Shell Company false    
Entity Emerging Growth Company true    
Entity Current Reporting Status Yes    
Document Period End Date Dec. 31, 2022    
Entity Filer Category Non-accelerated Filer    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2022    
Entity Ex Transition Period true    
Entity Common Stock Shares Outstanding   12,321,848  
Entity Public Float     $ 4.0
Document Annual Report true    
Document Transition Report false    
Entity File Number 001-40739    
Entity Incorporation State Country Code DE    
Entity Tax Identification Number 86-3218736    
Entity Address Address Line 1 3525 Del Mar Heights Rd    
Entity Address Address Line 2 322    
Entity Address City Or Town San Diego    
Entity Address State Or Province CA    
Entity Address Postal Zip Code 92130    
City Area Code 858    
Icfr Auditor Attestation Flag false    
Auditor Name Mayer Hoffman McCann, P.C.    
Auditor Location California    
Auditor Firm Id 199    
Local Phone Number 800-2543    
Security 12b Title Common Stock, par value $0.0001 per share    
Trading Symbol DRMA    
Security Exchange Name NASDAQ    
Entity Interactive Data Current Yes    
Amendment Description Dermata Therapeutics, Inc. (the “Company,” “Dermata,” “we,” “us,” or “our”) hereby amends its Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the SEC on February 21, 2023 (the “Form 10-K”), as set forth in this Amendment No. 1 on Form 10-K/A (this “Amendment”). This Amendment is being filed solely to amend and replace Part II, Item 9A. “Controls and Procedures” of the Form 10-K, to reflect the conclusion of the Company’s Principal Executive Officer and Principal Financial Officer that the Company’s internal controls over financial reporting were effective as of December 31, 2022. Except as described above and for currently-dated certifications of the Company’s principal executive officer and principal financial officer filed herewith as Exhibits 31.1 and 31.2, no other changes are being made to the Form 10-K and this Amendment does not modify, amend, or update in any way any of the financial or other information contained in the Form 10-K. Because no    
Common Warrants      
Document Information Line Items      
Security 12b Title Common Stock Purchase Warrants    
Trading Symbol DRMAW    
Security Exchange Name NASDAQ